Navigation Links
Northwest Bio Implements Major Balance Sheet Clean-Up
Date:12/2/2011

iously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Comp
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioSpace Spotlights Northwests Life Science Community
2. Northwest Bio Announces Interview of CEO Linda Powers in Todays CEO/CFO Publication
3. NORTHWEST BIO Announces Positive Third Quarter Progress
4. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
5. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
6. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
7. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
8. Northwest Biotherapeutics Announces Change and Expansion of Management Team
9. Northwest Biotherapeutics Announces Series of Financing Arrangements
10. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
11. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that its majority-owned subsidiary, Shandong Taibang Biological ... ("GMP") certification from the China Food and Drug ... production facility. As previously disclosed in the Company,s ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, announced today the ... Calgary in conjunction with co-authors from Kyoto University and ... company,s ongoing clinical research using dermal sheath cup (DSC) ... The paper entitled " Hair Follicle Dermal Stem ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Acquisition of Remainder of NexGen Diagnostics Captures Promising ... Intellectual ... BEC ), a leading developer of products that simplify and,automate complex ... acquire the remaining 80.1 percent of NexGen,Diagnostics LLC, a spin out ...
... Marks & Co. LP has partnered,with BlueStar Capital Management ... LP. The partnership also gives Carl Marks a stake ... and an,increased presence in the healthcare investment sector., ... which are,long and short public healthcare equities, in both ...
... announced today,the presentation of the results obtained so far ... and Dr. John Barrett* of the National,Heart, Lung, and ... Health (NIH) on Kiadis, lead product ATIR at the ... According to the NHLBI investigators the challenge in the ...
Cached Biology Technology:Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies 2Carl Marks Seeds New Healthcare Fund Through Strategic Partnership With BlueStar Capital Management 2Promising Data ATIR Studies Presented by NIH Investigators 2
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... an extraordinary ability to remember numerals that is superior ... December 4th issue of Current Biology, a publication of ... many biologists, who believe that humans are superior to ... Kyoto University. No one can imagine that chimpanzeesyoung chimpanzees ...
... sizes. Each cell is shaped in such a way as ... wrong and a cell does not adopt its dedicated shape, ... problems in the body. Researchers at the European Molecular Biology ... (AMOLF), The Netherlands, have now decoded a molecular mechanism that ...
... published today in Nature Genetics shows that some rearrangements ... thought. The work is likely to lead to new ... diagnosis of genomic disease. The scientists from the ... in the genome where rearrangements cause genetic diseases, so-called ...
Cached Biology News:Young chimps top adult humans in numerical memory 2How cells keep in shape 2Mutant sperm guide clinicians to new diseases 2Mutant sperm guide clinicians to new diseases 3
... dUTPase The thermostable dUTPase(pyrococcus ... PCR (using proofreading DNA polymerases). ... PCR reactions and dNTP solutions. ... proofreading DNA polymerase reaction can prevent ...
... an exciting product for cell-based kinetic assays ... the use of expensive HTS equipment, which ... the assay development stage. The NOVOstar offers ... as well as any other assay suitable ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
... Agilent Technologies introduces an enhanced ... ICP-MS for Windows 2000 and ... From September 2003, all new ... controlled by the new ChemStation ...
Biology Products: